Literature DB >> 32176310

A Systematic Review of Drug-Induced Pemphigoid.

Matthew J Verheyden1, Asli Bilgic, Dédée F Murrell.   

Abstract

Bullous pemphigoid is an autoimmune subepithelial disease characterised by pruritus followed by urticarial plaques and finally bullae on the skin and mucosa. Drug-associated bullous pemphigoid (DABP) is a term used to describe instances of bullous pemphigoid demonstrating clinical, histological, or immunopathological features identical or similar to those of the idiopathic form of bullous pemphigoid, associated with the systemic ingestion, or topical application of particular drugs. In this study, we conducted a comprehensive search of the literature according to PRISMA guidelines and a total of 170 publications were included in the final qualitative analysis. In conclusion, 89 drugs were implicated in DABP. The strongest evidence for DABP is seen with gliptins, PD-1/PD-L1 inhibitors, loop diuretics, penicillin and derivatives. An appreciation of the medications associated with bullous pemphigoid enables clinicians to identify potential cases of DABP earlier and cease the offending medication.

Entities:  

Keywords:  drug-associated; drug-associated bullous pemphigoid; bullous pemphigoid

Mesh:

Substances:

Year:  2020        PMID: 32176310      PMCID: PMC9207627          DOI: 10.2340/00015555-3457

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  100 in total

Review 1.  "Two-step" pemphigus induction by ACE-inhibitors.

Authors:  V Ruocco; R A Satriano; V Guerrera
Journal:  Int J Dermatol       Date:  1992-01       Impact factor: 2.736

Review 2.  Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.

Authors:  Anna Liza C Agero; Stephen W Dusza; Cristiane Benvenuto-Andrade; Klaus J Busam; Patricia Myskowski; Allan C Halpern
Journal:  J Am Acad Dermatol       Date:  2006-10       Impact factor: 11.527

3.  Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

4.  Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid.

Authors:  Outi Lindgren; Outi Varpuluoma; Jussi Tuusa; Jorma Ilonen; Laura Huilaja; Nina Kokkonen; Kaisa Tasanen
Journal:  Acta Derm Venereol       Date:  2019-05-01       Impact factor: 4.437

5.  Bullous pemphigoid induced by penicillamine in a patient with Wilson disease.

Authors:  Svetlana Popadic; Dusan Skiljevic; Ljiljana Medenica
Journal:  Am J Clin Dermatol       Date:  2009       Impact factor: 7.403

Review 6.  Bullous pemphigoid in a renal transplant recipient: a case report and review of the literature.

Authors:  Ting-Jui Chen; Ping-Chin Lai; Li-Cheng Yang; Tseng-Tong Kuo; Hong-Shang Hong
Journal:  Am J Clin Dermatol       Date:  2009       Impact factor: 7.403

Review 7.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

Review 8.  Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.

Authors:  Vivek Kumar; Neha Chaudhary; Mohit Garg; Charalampos S Floudas; Parita Soni; Abhinav B Chandra
Journal:  Front Pharmacol       Date:  2017-02-08       Impact factor: 5.810

9.  Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid.

Authors:  Sébastien Le Jan; Julie Plée; David Vallerand; Aurélie Dupont; Elodie Delanez; Anne Durlach; Patricia L Jackson; J Edwin Blalock; Philippe Bernard; Frank Antonicelli
Journal:  J Invest Dermatol       Date:  2014-07-19       Impact factor: 8.551

Review 10.  HLA Association with Drug-Induced Adverse Reactions.

Authors:  Wen-Lang Fan; Meng-Shin Shiao; Rosaline Chung-Yee Hui; Shih-Chi Su; Chuang-Wei Wang; Ya-Ching Chang; Wen-Hung Chung
Journal:  J Immunol Res       Date:  2017-11-23       Impact factor: 4.818

View more
  11 in total

1.  Relationship between bullous pemphigoid and metabolic syndrome: a 12-year case-control study conducted in China.

Authors:  Bingjie Zhang; Xinyi Chen; Yangchun Liu; Fangyuan Chen; Nan Yang; Li Li
Journal:  Ther Adv Chronic Dis       Date:  2022-10-15       Impact factor: 4.970

Review 2.  Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature.

Authors:  Aikaterini Tsiogka; Johann W Bauer; Aikaterini Patsatsi
Journal:  Acta Derm Venereol       Date:  2021-01-20       Impact factor: 3.875

Review 3.  Guselkumab-associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature.

Authors:  Martina Burlando; Niccolò Capurro; Astrid Herzum; Emanuele Cozzani; Aurora Parodi
Journal:  Dermatol Ther       Date:  2021-11-30       Impact factor: 3.858

4.  Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma.

Authors:  Hanna Eriksson; Johan Hansson; Britta Krynitz; Giuseppe Masucci; Ada Girnita; Jan Lapins; Auris O Huen; Hussein A Tawbi; Michael A Davies; Michael T Tetzlaff; Jonathan L Curry
Journal:  Acta Derm Venereol       Date:  2020-11-26       Impact factor: 3.875

Review 5.  Dyshidrosiform Bullous Pemphigoid.

Authors:  Philip R Cohen
Journal:  Medicina (Kaunas)       Date:  2021-04-20       Impact factor: 2.430

6.  Bullous Pemphigoid Associated with Multiple System Atrophy: Case Series.

Authors:  Andrew Snedden; Jennifer Sharif; John Newsham; Christopher Kobylecki
Journal:  Mov Disord Clin Pract       Date:  2021-02-25

Review 7.  Bullous pemphigoid in diabetic patients treated by gliptins: the other side of the coin.

Authors:  Karim Chouchane; Giovanni Di Zenzo; Dario Pitocco; Laura Calabrese; Clara De Simone
Journal:  J Transl Med       Date:  2021-12-20       Impact factor: 5.531

8.  Absolving COVID-19 Vaccination of Autoimmune Bullous Disease Onset.

Authors:  Roberto Russo; Giulia Gasparini; Emanuele Cozzani; Federica D'Agostino; Aurora Parodi
Journal:  Front Immunol       Date:  2022-02-18       Impact factor: 7.561

9.  Self-resolving bullous pemphigoid induced by cemiplimab.

Authors:  Mattia Fabio Molle; Niccolò Capurro; Astrid Herzum; Claudia Micalizzi; Emanuele Cozzani; Aurora Parodi
Journal:  Dermatol Ther       Date:  2022-03-29       Impact factor: 3.858

10.  Three cases of vesiculobullous non-IgE-mediated cutaneous reactions to tozinameran (Pfizer-BioNTech COVID-19 vaccine).

Authors:  L Juay; N S Chandran
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-08-16       Impact factor: 9.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.